MEDIUM confidence: 100% data completeness, but the composite (51) sits in the indecisive 30–70 range — strong-buy and short calls require a more decisive composite. What does confidence mean?
Technical context for active traders — derived from price, the 50/200-day moving averages, the 52-week range, and recent volume. Not part of the QScore.
Not enough return history to estimate factor exposures — 26 of 36 months required. This stock is too recently listed (or has too short a price history) for a reliable Fama-French regression.
Avg target $57 (last qtr, 2 analysts) → $0 (last mo, 0) (-100.0%).
Buy-rated share 92% → 93% over ~3 months (+1pp).
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| May 2026 | $0.16 | $0.13 | -19.2% |
| Feb 2026 | $0.15 | $0.06 | -61.3% |
| Nov 2025 | $0.42 | $0.33 | -21.4% |
| Aug 2025 | $0.40 | $0.06 | -85.0% |
| May 2025 | $0.37 | $-0.04 | -110.8% |
| Feb 2025 | $0.40 | $-0.21 | -152.5% |
| Nov 2024 | $0.32 | $-0.03 | -109.4% |
| Aug 2024 | $0.29 | $0.01 | -96.6% |
| Metric (USD) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $1.3B— | $1.6B+28.0% | $1.9B+14.9% | $2.1B+11.4% | $2.3B+9.1% |
| EPS (dil.) | $-0.72— | $-1.23n/m | $-1.08n/m | $-0.29n/m | $0.42n/m |
| Free Cash Flow | -$62M— | $76Mn/m | -$1M-101.6% | $84Mn/m | $166M+97.1% |
| Gross Margin | 14.4% | 20.8%+6.4pp | 19.2%-1.6pp | 20.1%+0.9pp | 1.8%-18.4pp |
| Operating Margin | 11.0% | 5.6%-5.4pp | 4.1%-1.5pp | 6.6%+2.5pp | 7.4%+0.8pp |
| Net Margin | -3.8% | -5.0%-1.2pp | -3.8%+1.2pp | -1.8%+2.0pp | 3.1%+4.9pp |
Absolute figures with year-over-year change. Margins show the level with the change in percentage points (pp). “n/m” = not meaningful (prior ≤ 0); ⚠ marks a large percentage off a small base — read the dollar figure.
Net insider -$219K over 180 days (0 open-market buys, 2 sells). Insider buying is the informative signal; routine selling is normal.
Short interest, days-to-cover, and institutional-ownership change require a data-plan upgrade (not yet available).
Forward-return IC, quintile spread & hit rate publish on /performance as the tracking panel accrues enough no-look-ahead history.
Net buyback (repurchases less issuance) ÷ market cap, plus trailing dividend yield.
The QScore of 51 for American Healthcare REIT indicates a neutral outlook, with the short-term score being slightly more favorable than the long-term score. The stock scores high on growth and momentum, driven by strong revenue and EPS growth of 9.1% and 244.8%, respectively, as well as a 41% return over the past year. However, it trades at a premium, with a P/E of 87.6, and exhibits weak profitability, with an ROE of only 3.4%. The divergence between long-term and short-term scores suggests some uncertainty in the stock's prospects.